JP2018516853A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516853A5 JP2018516853A5 JP2017551294A JP2017551294A JP2018516853A5 JP 2018516853 A5 JP2018516853 A5 JP 2018516853A5 JP 2017551294 A JP2017551294 A JP 2017551294A JP 2017551294 A JP2017551294 A JP 2017551294A JP 2018516853 A5 JP2018516853 A5 JP 2018516853A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- seq
- antibody
- isolated antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562140913P | 2015-03-31 | 2015-03-31 | |
| US62/140,913 | 2015-03-31 | ||
| PCT/EP2016/056973 WO2016156440A1 (en) | 2015-03-31 | 2016-03-30 | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020178437A Division JP2021038226A (ja) | 2015-03-31 | 2020-10-23 | 新規ｉｌ３３型、変異型のｉｌ３３、抗体、アッセイ及びそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018516853A JP2018516853A (ja) | 2018-06-28 |
| JP2018516853A5 true JP2018516853A5 (enExample) | 2019-05-16 |
| JP6862351B2 JP6862351B2 (ja) | 2021-04-21 |
Family
ID=55640748
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551294A Active JP6862351B2 (ja) | 2015-03-31 | 2016-03-30 | 新規ｉｌ３３型、変異型のｉｌ３３、抗体、アッセイ及びそれらの使用方法 |
| JP2020178437A Pending JP2021038226A (ja) | 2015-03-31 | 2020-10-23 | 新規ｉｌ３３型、変異型のｉｌ３３、抗体、アッセイ及びそれらの使用方法 |
| JP2023173336A Pending JP2024001166A (ja) | 2015-03-31 | 2023-10-05 | 新規ｉｌ３３型、変異型のｉｌ３３、抗体、アッセイ及びそれらの使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020178437A Pending JP2021038226A (ja) | 2015-03-31 | 2020-10-23 | 新規ｉｌ３３型、変異型のｉｌ３３、抗体、アッセイ及びそれらの使用方法 |
| JP2023173336A Pending JP2024001166A (ja) | 2015-03-31 | 2023-10-05 | 新規ｉｌ３３型、変異型のｉｌ３３、抗体、アッセイ及びそれらの使用方法 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10668150B2 (enExample) |
| EP (3) | EP3277717B1 (enExample) |
| JP (3) | JP6862351B2 (enExample) |
| KR (1) | KR102261618B1 (enExample) |
| CN (1) | CN108064236B (enExample) |
| AU (3) | AU2016239331C1 (enExample) |
| CA (1) | CA2982400C (enExample) |
| CL (2) | CL2017002433A1 (enExample) |
| CO (1) | CO2017010753A2 (enExample) |
| CY (1) | CY1123925T1 (enExample) |
| DK (1) | DK3277717T3 (enExample) |
| ES (1) | ES2886114T3 (enExample) |
| HR (1) | HRP20210096T1 (enExample) |
| HU (1) | HUE053097T2 (enExample) |
| IL (2) | IL254551A0 (enExample) |
| LT (1) | LT3277717T (enExample) |
| MX (1) | MX387295B (enExample) |
| MY (1) | MY190209A (enExample) |
| NZ (1) | NZ736026A (enExample) |
| PL (1) | PL3277717T3 (enExample) |
| PT (1) | PT3277717T (enExample) |
| RS (1) | RS61438B1 (enExample) |
| RU (1) | RU2736299C2 (enExample) |
| SG (1) | SG11201707593UA (enExample) |
| SI (1) | SI3277717T1 (enExample) |
| SM (1) | SMT202100086T1 (enExample) |
| TW (1) | TWI721973B (enExample) |
| WO (1) | WO2016156440A1 (enExample) |
| ZA (1) | ZA201707355B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9758578B2 (en) | 2013-12-26 | 2017-09-12 | Mitsubishi Tanabe Pharma Corporation | Human anti-IL-33 neutralizing monoclonal antibody |
| EP3218515B1 (en) | 2014-11-10 | 2023-04-26 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for il-33-mediated disorders |
| CA2960297A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| MY190209A (en) * | 2015-03-31 | 2022-04-05 | Medimmune Ltd | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same |
| PE20181952A1 (es) | 2016-04-27 | 2018-12-17 | Pfizer | Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos |
| JOP20190093A1 (ar) | 2016-10-28 | 2019-04-25 | Lilly Co Eli | أجسام مضادة لـ il-33 واستخداماتها |
| TWI857389B (zh) | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| PL3558369T3 (pl) * | 2016-12-21 | 2025-06-23 | Cephalon Llc | Przeciwciała specyficznie wiążące się z ludzką il-15 i ich zastosowania |
| MX2019012171A (es) | 2017-04-13 | 2019-11-25 | Regeneron Pharma | Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1. |
| JP7657440B2 (ja) | 2017-06-12 | 2025-04-07 | ブルーフィン バイオメディシン， インコーポレイテッド | 抗－ｉｌ１ｒａｐ抗体および抗体薬物コンジュゲート |
| CN115920032A (zh) | 2017-08-31 | 2023-04-07 | 田边三菱制药株式会社 | 含有il-33拮抗剂的子宫内膜异位症治疗剂 |
| CN107973849B (zh) * | 2017-11-30 | 2020-07-28 | 畜科生物工程有限公司 | 一种用于增强猪疫苗免疫效果的蛋白质及其应用 |
| WO2019183375A1 (en) * | 2018-03-22 | 2019-09-26 | Eureka Therapeutics, Inc. | Antibody agents specifically recognizing monocarboxylate transporter 4 and uses thereof |
| IL307286B1 (en) | 2018-04-11 | 2025-11-01 | Regeneron Pharma | Methods and compositions for quantifying il-33 |
| WO2020054871A1 (ja) * | 2018-09-14 | 2020-03-19 | 田辺三菱製薬株式会社 | ヒト抗ｉｌ－３３モノクローナル抗体含有医薬用組成物 |
| CN111434687B (zh) * | 2019-01-15 | 2022-03-11 | 南京赛新生物科技有限公司 | 一种抗体及其应用 |
| CN111434680B (zh) * | 2019-01-15 | 2021-11-23 | 南京赛新生物科技有限公司 | 一种与il33相关疾病的抗原表位肽及其应用 |
| US20220272953A1 (en) * | 2019-07-29 | 2022-09-01 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric il33 |
| CN110567861B (zh) * | 2019-09-09 | 2021-12-21 | 浙江普罗亭健康科技有限公司 | 基于质谱流式检测技术筛查具有免疫原性抗原肽的试剂盒及检测方法 |
| WO2021089563A1 (en) | 2019-11-04 | 2021-05-14 | Medimmune Limited | Methods of using il-33 antagonists |
| EP4055044A1 (en) | 2019-11-04 | 2022-09-14 | MedImmune Limited | Anti il-33 therapeutic agent for treating renal disorders |
| CN115315527A (zh) * | 2020-03-13 | 2022-11-08 | 免疫医疗有限公司 | 用于治疗il33中存在风险等位基因的受试者的治疗方法 |
| CA3174680A1 (en) | 2020-03-13 | 2021-09-16 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| WO2021204707A1 (en) | 2020-04-06 | 2021-10-14 | Medimmune Limited | Treating acute respiratory distress syndrome with il-33 axis binding antagonists |
| BR112022022620A2 (pt) * | 2020-05-11 | 2022-12-20 | Medimmune Ltd | Formulações de anticorpos anti-il-33 |
| IL298075A (en) * | 2020-05-12 | 2023-01-01 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | St2 antigen binding protein |
| CN111378037B (zh) * | 2020-06-01 | 2020-09-01 | 南京诺艾新生物技术有限公司 | 一种抗hIL-33人源化单抗及其应用 |
| EP4295154A1 (en) | 2021-02-18 | 2023-12-27 | F. Hoffmann-La Roche AG | Method for resolving complex, multistep antibody interactions |
| CN113234157B (zh) * | 2021-07-09 | 2021-09-21 | 上海普铭生物科技有限公司 | 亲和力成熟的人源化抗人il-33单克隆抗体及其应用 |
| DK4244252T3 (da) * | 2021-08-27 | 2024-09-02 | Medimmune Ltd | Behandling af kronisk obstruktiv lungesygdom med et anti-interleukin-33-antistof |
| WO2023086807A1 (en) * | 2021-11-10 | 2023-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| TW202402790A (zh) | 2022-03-25 | 2024-01-16 | 英商梅迪繆思有限公司 | 減少呼吸系統感染之方法 |
| WO2024038187A1 (en) | 2022-08-19 | 2024-02-22 | Medimmune Limited | Assay for detection of il-33 |
| EP4573121A1 (en) | 2022-08-19 | 2025-06-25 | MedImmune Limited | Method of selecting patients for treatment with an il-33 axis antagonist |
| WO2024038186A1 (en) | 2022-08-19 | 2024-02-22 | Medimmune Limited | Treatment of acute respiratory failure |
| TW202423972A (zh) | 2022-08-26 | 2024-06-16 | 英商梅迪繆思有限公司 | 使用抗介白素－３３抗體的氣喘治療 |
| KR20250168673A (ko) | 2023-04-12 | 2025-12-02 | 아스트라제네카 아베 | Steap2-표적화 화합물 및 이의 용도 |
| AR134489A1 (es) * | 2023-11-27 | 2026-01-21 | Glaxosmithkline Ip Dev Ltd | Proteinas de unión a antígeno |
| WO2025120567A1 (en) | 2023-12-07 | 2025-06-12 | Medimmune Limited | Method of treatment of asthma |
| WO2025210099A1 (en) | 2024-04-04 | 2025-10-09 | Medimmune Limited | Method of treatment and selecting a subject |
| WO2025242618A1 (en) | 2024-05-20 | 2025-11-27 | Medimmune Limited | Bronchiectasis treatment |
| WO2025242619A1 (en) | 2024-05-20 | 2025-11-27 | Medimmune Limited | Treatment for mucus plugging |
| WO2025252012A1 (en) * | 2024-06-03 | 2025-12-11 | Fbd Biologics Limited | Engineered il-7 variants and methods of use thereof |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| EP0428534B1 (en) | 1988-06-14 | 1995-03-29 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5136964A (en) | 1989-01-19 | 1992-08-11 | Arnold J. Cook | Warning device for windsurfing craft |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| EP0521985B1 (en) | 1990-03-20 | 1997-09-24 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| DE69130709T3 (de) | 1990-10-05 | 2005-12-22 | Celldex Therapeutics, Inc. | Gezielte immunostimulierung mit bispezifischen stoffen |
| EP0557300B1 (en) | 1990-10-29 | 1997-11-19 | Chiron Corporation | Bispecific antibodies, method of production, and uses thereof |
| ES2178635T3 (es) | 1990-11-09 | 2003-01-01 | Stephen D Gillies | Inmunoconjugados de citoquinas. |
| DE69214709T2 (de) | 1991-04-26 | 1997-02-20 | Surface Active Ltd | Neue Antikörper und Verfahren zu ihrer Verwendung |
| ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| EP0627940B1 (en) | 1992-03-05 | 2003-05-07 | Board of Regents, The University of Texas System | Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6828422B1 (en) | 1995-08-18 | 2004-12-07 | Morphosys Ag | Protein/(poly)peptide libraries |
| WO1997008320A1 (en) | 1995-08-18 | 1997-03-06 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
| WO2001002588A2 (en) | 1999-07-02 | 2001-01-11 | Morphosys Ag | Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| BRPI0108923B8 (pt) | 2000-03-03 | 2021-05-25 | Cambridge Antibody Tech Limited | elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina |
| JP4368196B2 (ja) | 2000-11-17 | 2009-11-18 | ユニバーシティー オブ ロチェスター | 真核細胞において免疫グロブリン分子を製造および同定するインビトロにおける方法 |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| CN1305905C (zh) | 2002-03-22 | 2007-03-21 | Aprogen株式会社 | 人源化抗体及其制备方法 |
| NZ549040A (en) * | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| KR101544108B1 (ko) | 2006-09-08 | 2015-08-13 | 애브비 바하마스 리미티드 | 인터루킨-13 결합 단백질 |
| WO2008137552A2 (en) | 2007-05-02 | 2008-11-13 | Medimmune, Llc | Anti-rage antibodies and methods of use thereof |
| EP2069784A4 (en) * | 2007-05-18 | 2009-11-18 | Medimmune Llc | IL-33 IN INFLAMMATORY DISEASE |
| WO2009055074A2 (en) | 2007-10-25 | 2009-04-30 | Wyeth | Erbb2 binding proteins and use thereof |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| JP6013915B2 (ja) * | 2010-11-17 | 2016-10-25 | 中外製薬株式会社 | 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子 |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| JO3623B1 (ar) | 2012-05-18 | 2020-08-27 | Amgen Inc | البروتينات المرتبطة بمولد المستضاد st2 |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| MY190209A (en) * | 2015-03-31 | 2022-04-05 | Medimmune Ltd | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same |
-
2016
- 2016-03-30 MY MYPI2017703606A patent/MY190209A/en unknown
- 2016-03-30 KR KR1020177030936A patent/KR102261618B1/ko active Active
- 2016-03-30 DK DK16712353.8T patent/DK3277717T3/da active
- 2016-03-30 NZ NZ736026A patent/NZ736026A/en unknown
- 2016-03-30 EP EP16712353.8A patent/EP3277717B1/en active Active
- 2016-03-30 ES ES16712353T patent/ES2886114T3/es active Active
- 2016-03-30 SM SM20210086T patent/SMT202100086T1/it unknown
- 2016-03-30 PL PL16712353T patent/PL3277717T3/pl unknown
- 2016-03-30 RU RU2017134909A patent/RU2736299C2/ru active
- 2016-03-30 AU AU2016239331A patent/AU2016239331C1/en active Active
- 2016-03-30 EP EP20169253.0A patent/EP3733701A1/en not_active Ceased
- 2016-03-30 MX MX2017012616A patent/MX387295B/es unknown
- 2016-03-30 CA CA2982400A patent/CA2982400C/en active Active
- 2016-03-30 PT PT167123538T patent/PT3277717T/pt unknown
- 2016-03-30 EP EP23219513.1A patent/EP4374916A3/en active Pending
- 2016-03-30 CN CN201680019480.3A patent/CN108064236B/zh active Active
- 2016-03-30 JP JP2017551294A patent/JP6862351B2/ja active Active
- 2016-03-30 LT LTEP16712353.8T patent/LT3277717T/lt unknown
- 2016-03-30 RS RS20210171A patent/RS61438B1/sr unknown
- 2016-03-30 HR HRP20210096TT patent/HRP20210096T1/hr unknown
- 2016-03-30 SI SI201631069T patent/SI3277717T1/sl unknown
- 2016-03-30 US US15/562,228 patent/US10668150B2/en active Active
- 2016-03-30 SG SG11201707593UA patent/SG11201707593UA/en unknown
- 2016-03-30 WO PCT/EP2016/056973 patent/WO2016156440A1/en not_active Ceased
- 2016-03-30 HU HUE16712353A patent/HUE053097T2/hu unknown
- 2016-03-31 TW TW105110432A patent/TWI721973B/zh active
-
2017
- 2017-09-18 IL IL254551A patent/IL254551A0/en unknown
- 2017-09-27 CL CL2017002433A patent/CL2017002433A1/es unknown
- 2017-10-23 CO CONC2017/0010753A patent/CO2017010753A2/es unknown
- 2017-10-30 ZA ZA2017/07355A patent/ZA201707355B/en unknown
-
2019
- 2019-10-17 AU AU2019250213A patent/AU2019250213B2/en active Active
-
2020
- 2020-04-10 US US16/845,121 patent/US11738081B2/en active Active
- 2020-09-02 CL CL2020002269A patent/CL2020002269A1/es unknown
- 2020-10-23 JP JP2020178437A patent/JP2021038226A/ja active Pending
-
2021
- 2021-01-10 IL IL280045A patent/IL280045B/en unknown
- 2021-02-17 CY CY20211100134T patent/CY1123925T1/el unknown
- 2021-10-25 AU AU2021257881A patent/AU2021257881B2/en active Active
-
2023
- 2023-07-05 US US18/346,884 patent/US20240016929A1/en active Pending
- 2023-10-05 JP JP2023173336A patent/JP2024001166A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516853A5 (enExample) | ||
| JP2023113686A (ja) | ｐＨ依存的抗体の調製方法 | |
| RU2017134909A (ru) | Новая форма IL33, мутировавшие формы IL33, антитела, анализы и способы их применения | |
| JP2010538608A5 (enExample) | ||
| JP2019527553A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| JP2019054802A5 (enExample) | ||
| RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 | |
| JP2015504421A5 (enExample) | ||
| JP2017052784A5 (enExample) | ||
| JP2017149720A5 (enExample) | ||
| JP2009225799A5 (enExample) | ||
| JP2020524510A5 (enExample) | ||
| JP2010502183A5 (enExample) | ||
| JP2011207882A5 (enExample) | ||
| JP2012501670A5 (enExample) | ||
| FI3826667T3 (fi) | Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi | |
| JP2016516400A5 (enExample) | ||
| JPWO2020114480A5 (enExample) | ||
| JP2018522888A5 (enExample) | ||
| RU2021129189A (ru) | Антитела против фактора свертывания xi | |
| JP2012530487A5 (enExample) | ||
| JP2017524362A5 (enExample) | ||
| JP2017521054A5 (enExample) | ||
| JP2015508056A5 (enExample) |